ArticleApplied microbiology and biotechnology2020
Smart drug delivery against Helicobacter pylori: pectin-coated, mucoadhesive liposomes with antiadhesive activity and antibiotic cargo.
Article in Applied microbiology and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 55 citations in OpenAlex.
- Electrostatic-tailored Leciplex system of ketoconazole for boosted ocular pharmacology and cytotoxicity assessment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Extremely oxygen-sensitive next-generation probiotics: can current microcomposite formulations ensure effective colonic delivery?Microsystems & nanoengineering · 2026Review
- Development of a mucoadhesive drug delivery system and its interaction with gastric cells.Beilstein journal of nanotechnology · 2025Article
- Consortium ofAntibiotics (Basel, Switzerland) · 2024Article
- Lipid-Based Nanoformulations for Drug Delivery: An Ongoing Perspective.Pharmaceutics · 2024Review
- Opportunities forMicroorganisms · 2024Review
- Targeted nanotherapeutics for the treatment of Helicobacter pylori infection.Journal of biomedical science · 2024Review
- High molecular/low acetylated chitosans reduce adhesion of Campylobacter jejuni to host cells by blocking JlpA.Applied microbiology and biotechnology · 2024Article
- The effects and mechanisms of natural products onFrontiers in cellular and infection microbiology · 2024Review
- Treatment ofHeliyon · 2023Review
- Campylobacter jejuni: targeting host cells, adhesion, invasion, and survival.Applied microbiology and biotechnology · 2023Review
- Controlled Drug Release from Nanoengineered Polysaccharides.Pharmaceutics · 2023Review
- Coating Materials to Increase the Stability of Liposomes.Polymers · 2023Review
- A review on the research progress on non-pharmacological therapy ofFrontiers in microbiology · 2023Review
- Mucoadhesive carriers for oral drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2022Review
- Article
- Scope and Limitations of Current Antibiotic Therapies againstPharmaceutics · 2022Review
- Pelargonidin-Antioxidants (Basel, Switzerland) · 2022Article
- Advances in Nanostructures for Antimicrobial Therapy.Materials (Basel, Switzerland) · 2022Review
- New Advances in Nano-Drug Delivery Systems:Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The first step in the development of Helicobacter pylori pathogenicity is the receptor-mediated adhesion to the gastric epithelium. Inhibition of outer membrane proteins of H. pylori (e.g. BabA) by antiadhesive drugs will contribute to reduced recolonization and infection. Pectin from apple inhibits the BabA and LPS-mediated adhesion of H. pylori to human stomach cells. Pectin-coated liposomes with encapsulated amoxicillin were characterized for polydispersity, zeta potential, encapsulation efficiency, stability, and amoxicillin release. Coated liposomes did not influence the viability of AGS and HT29-MTX cells up to 100 μg/mL but exert cytotoxicity against H. pylori at 10 μg/mL. Pectin-coating of liposomes provoked direct interaction and subsequent binding of the particles to surface structures of H. pylori, and interaction with mucus from porcine stomach and mucus secreted by HT29-MTX cells. Laser scanning microscopy of H. pylori and AGS cells together with liposomes indicated co-aggregation. The mucoadhesive effect seems interesting as stomach cells are covered by a mucus layer. H. pylori is able to penetrate and cross the mucin rapidly to reach pH-neutral epithelium to escape the acidic environment, followed by interaction with epithelial cells. In summary, all experimental evidence is consistent with a specific interaction of pectin-coated liposomes with mucins and surface structures of H. pylori. As the coated liposomes show mucoadhesion to the negatively charged mucins, docking to stomach mucin, mucus penetration, and recognition of and adhesion to H. pylori, they can be considered a novel type of multifunctional drug carriers for local antibiotic therapy against H. pylori. KEY POINTS: • Smart, multifunctional mucoadhesive liposomes • Specific targeting against BabA/LPS of Helicobacter pylori • Inhibition of bacterial adhesion of H. pylori to human host cells • Release of antibiotic cargo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.